Abstract: The invention is directed to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.

Abstract: The present invention relates to a population of cells comprising hepatic stem-like cells and therapeutic use thereof, for the treatment and the prevention of fulminant liver disorders. The hepatic stem-like cells according to the invention may be safely and reproducibly generated from pluripotent stem cells. In addition, although the hepatic stem-like cells according to the invention do not display the phenotype of physiologically mature hepatic cells, as they are lacking the albumin expression marker (ALB?), they may still be transplanted in a diseased liver with acute failure, rescue the diseased liver and promote liver regeneration. Moreover, various protocols of preparation of hepatic stem-like cells according to the invention may be implemented, all resulting in high quality and high yield of production. Finally, the hepatic stem-like cells according to the invention may be cryopreserved and may also be prepared as spheroid particles.

Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.

Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.

Abstract: A drone chassis including an external structure that deforms elastically in bending, and a set of cables connecting at least one support, intended to support a functional element of the drone, to the external structure. The set of cables includes elastic cables deforming elastically in traction under a tensile stress above a natural deformation threshold, the set of cables being attached at several points on the external structure, referred to as attachment points, to hold the at least one support in a stable position with respect to the external structure. The elastic cables are attached under stress by applying an initial tensile stress and maintains the initial tensile stress by attaching to the external structure. An additional tensile stress applied to the cables attached under stress causes a deformation under traction of the cables only as from a threshold that is above the natural deformation threshold of the cables.

Abstract: The present invention provides crosslinking pairs of hydrogel precursor polymers, dynamic covalent hydrogels prepared from such crosslinking pairs of hydrogel precursors, pharmaceutical compositions comprising such precursors or hydrogels and uses thereof in a variety of applications.

Abstract: A method for chemically functionalizing a cellulosic material using a diazo compound, and the functionalized cellulosic materials obtained by the method. The cellulosic materials may be functionalized with a functional groups selected from hydrophobic agents, catalyzing agents, sensing agent, diagnostic agents, printing agents chelating agents, ligands, antioxidants, antimicrobial agents, or drugs. Also, the uses of functionalized cellulosic materials obtained by the method in a variety of applications.

Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.

Abstract: In the field of immunotherapy, a chimeric antigen receptor (CAR) specific for-human CD45RC. Also, the immune cells expressing this CAR and the use thereof as a medicament. In particular, the use of this CAR for preventing or treating CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, lymphoma or cancer), or graft-versus-host disease (GVHD).